Clinical Scenario

Cerebral hemangioblastoma is a vascular tumour of the central nervous system. Both symptomatic lesions and, in appropriate clinical circumstances, asymptomatic lesions are managed operatively, with complete removal of the solid tumour component as the primary aim.

Treatment Approach (partial overview)

The cornerstone of first-line management is complete surgical resection of the solid tumour component. The protocol specifies a structured pre-operative pharmacological preparation for lesions at certain anatomical locations, as well as a peri-operative intervention that may be considered in larger solid tumours to minimise intraoperative bleeding risk.

The complete sequence — including pharmacological steps, timing, post-operative reduction schedule, and surgical specifics — is detailed in the full structured protocol below.

Treatment Goals

The primary endpoint is confirmation of complete resection of the solid tumour on postoperative contrast-enhanced MRI at the surgical site. Where applicable, resolution of haematological sequelae attributable to the tumour mass is an additional marker of successful treatment.

References

DOI: 10.47739/2333-7125/1016

If no VHL disease is known both symptomatic and asymptomatic hemangioblastomas should be surgically resected completely for histological analysis.
There is general consent that symptomatic hemangioblastomas should be treated.
The goal of operative treatment is always the complete resection of the solid tumor component.
For all cerebellar and spinal hemangioblastomas we recommend a pre-treatment with dexamethasone (4 mg taken 4 times a day) for 3 days and a gradual reduction over the cause of one week after the second postoperative day.
Preoperative embolization can be helpful in large solid tumors to prevent perioperative hemorrhage.
In patients with single lesions without VHL disease a 3 months postoperative follow up by MRI with gadolinium is recommended at the site of surgery.
If radiographic findings show a complete resection of the tumor no further follow up is necessary since recurrences are extremely rare.
Approximately 5% of patients develop polyglobulia, which can be cured by removing the solid tumor mass.

View source ↗

Surgical Treatment of Cerebral Hemangioblastoma: First-Line Management

References